Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ACACA | Q13085 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | OXTR | P30559 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680885 | 0.85 | OXTR (0.58) | ACACBACACAHRH3HSD11B1HPGD | |
| SCHEMBL3386973 | 0.80 | HRH3 (0.66) | ACACBACACAHRH3 | |
| SCHEMBL23675231 | 0.79 | ACACB (0.48) | ACACBACACAHSD11B1HPGDLRRK2 | |
| SCHEMBL31482897 | 0.79 | ACACB (0.48) | ACACBACACAHSD11B1HPGDLRRK2 | |
| SCHEMBL6279698 | 0.78 | HPGD (0.71) | PKMHSD11B1HPGDLRRK2MGLL | |
| SCHEMBL17895473 | 0.75 | HRH3 (0.54) | PKMHRH3HPGD | |
| SCHEMBL29484293 | 0.75 | HRH3 (0.54) | PKMHRH3HPGD | |
| SCHEMBL4512607 | 0.75 | HSD11B1 (0.58) | PKMHSD11B1HPGDLRRK2MGLL | |
| SCHEMBL2671744 | 0.73 | HTR7 (0.56) | HTR1AHPGD | |
| SCHEMBL17615014 | 0.72 | HSD11B1 (0.51) | PKMHSD11B1HPGDLRRK2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HTR1A 1087/4885ACACB 577/4885ACACA 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.